{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:02:43Z","timestamp":1787788963984,"version":"build-2784847793"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.yebeh.2019.106580","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T17:50:49Z","timestamp":1573581049000},"page":"106580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events"],"prefix":"10.1016","volume":"102","author":[{"given":"Neil","family":"Brickel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Hewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeni","family":"De'Ath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Daniluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpesh","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Catherine","family":"Boll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somsak","family":"Tiamkao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Vorobyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2019.106580_bb0005","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","article-title":"Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy","volume":"76","author":"French","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.106580_bb0010","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","article-title":"Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy","volume":"75","author":"Brodie","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.106580_bb0015","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/01.wnl.0000259034.45049.00","article-title":"Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures","volume":"68","author":"Porter","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.106580_bb0020","series-title":"Committee for Medicinal Products for Human Use (CHMP) assessment report: Trobalt","author":"European Medicines Agency (EMA)","year":"2011"},{"key":"10.1016\/j.yebeh.2019.106580_bb0025","series-title":"POTIGA prescribing information","author":"GlaxoSmithKline (GSK)","year":"2013"},{"key":"10.1016\/j.yebeh.2019.106580_bb0030","series-title":"Ezogabine highlights of prescribing information","author":"FDA","year":"2012"},{"key":"10.1016\/j.yebeh.2019.106580_bb0035","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jamadermatol.2013.8895","article-title":"Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine","volume":"150","author":"Garin Shkolnik","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.yebeh.2019.106580_bb0040","series-title":"Trobalt (retigabine): variation assessment report","author":"European Medicines Agency (EMA)","year":"2013"},{"key":"10.1016\/j.yebeh.2019.106580_bb0045","series-title":"Procedural steps taken and scientific information after the authorisation","article-title":"Tropalt","author":"European Medicines Agency (EMA)","year":"2016"},{"key":"10.1016\/j.yebeh.2019.106580_bb0050","first-page":"339","article-title":"Pigmentary abnormalities (discoloration) associated with ezogabine\/retigabine treatment: non clinical aspects","volume":"15","author":"Prescott","year":"2015","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2019.106580_bb0055","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/acs.chemrestox.8b00313","article-title":"An investigation into retigabine (ezogabine) associated dyspigmentation in rat eyes by MALDI imaging mass spectrometry","volume":"32","author":"Groseclose","year":"2019","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.yebeh.2019.106580_bb0060","series-title":"68th annual meeting of the American Epilepsy Society (AES)","article-title":"Pigmentary abnormalities (discoloration) associated with ezogabine\/retigabine treatment: nonclinical aspects","author":"Prescott","year":"2014"},{"key":"10.1016\/j.yebeh.2019.106580_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.seizure.2015.06.002","article-title":"Efficacy and safety of ezogabine\/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures","volume":"30","author":"Lerche","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.106580_bb0070","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.yebeh.2016.05.018","article-title":"Efficacy and safety of retigabine\/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: a randomized, placebo-controlled phase III study","volume":"61","author":"Lim","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2019.106580_bb0075","first-page":"S32","article-title":"Evaluation of voiding dysfunction and measurement of bladder volume","volume":"6","author":"Kelly","year":"2004","journal-title":"Rev Urol"},{"key":"10.1016\/j.yebeh.2019.106580_bb0080","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/01.ju.0000138155.33749.f4","article-title":"Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats","volume":"172","author":"Streng","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.yebeh.2019.106580_bb0085","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.yebeh.2009.09.003","article-title":"Binasal visual field defects are not specific to vigabatrin","volume":"16","author":"Gonzalez","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.106580_bb0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eplepsyres.2010.09.004","article-title":"Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy","volume":"92","author":"Sergott","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.106580_bb0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1586\/17469899.2014.917961","article-title":"Vigabatrin-associated visual field loss: past, present and future","volume":"9","author":"Sergott","year":"2014","journal-title":"Expert Rev Ophthalmol"},{"key":"10.1016\/j.yebeh.2019.106580_bb0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1059-1311(03)00082-7","article-title":"The effect of antiepileptic drugs on visual performance","volume":"13","author":"Hilton","year":"2004","journal-title":"Seizure"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550501930650X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550501930650X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:29:29Z","timestamp":1761503369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550501930650X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":20,"alternative-id":["S152550501930650X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106580","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106580"}}